Table 1.

The distribution of study participants into individualised groups

Group	Regimen	N	Dose (mg/kg)
1	VRC07-523LS/Placebo	4/1	5 mg/kg SC one dose
2	VRC07-523LS/Placebo	4/1	10 mg/kg SC one dose
3	VRC07-523LS/Placebo	4/1	5 mg/kg SC with one repeat dose at 12 weeks
4	VRC07-523LS/Placebo	4/1	10 mg/kg SC with one repeat dose at 24 weeks
5	PGT121/Placebo	4/1	3 mg/kg SC one dose
6	PGT121/Placebo	4/1	3 mg/kg SC with one repeat dose at 12 weeks
7	VRC07-523LS+PGT121/Placebo	4/1	5 mg/kg SC+3 mg/kg SC one dose

SC, subcutaneously